Skip to content
Citation only via OpenAlex

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome

Erin M. Hill‐Burns, Justine W. Debelius, James T. Morton, William T. Wissemann, Matthew R. Lewis, Zachary D. Wallen, Shyamal D. Peddada, Stewart A. Factor, Eric Molho, Cyrus P. Zabetian, Rob Knight, Haydeh Payami

Movement Disorders · 2017 · ▲ 877 citations

Abstract

BACKGROUND: There is mounting evidence for a connection between the gut and Parkinson's disease (PD). Dysbiosis of gut microbiota could explain several features of PD. OBJECTIVE: The objective of this study was to determine if PD involves dysbiosis of gut microbiome, disentangle effects of confounders, and identify candidate taxa and functional pathways to guide research. METHODS: A total of 197 PD cases and 130 controls were studied. Microbial composition was determined by 16S rRNA gene sequencing of DNA extracted from stool. Metadata were collected on 39 potential confounders including medications, diet, gastrointestinal symptoms, and demographics. Statistical analyses were conducted while controlling for potential confounders and correcting for multiple testing. We tested differences in the overall microbial composition, taxa abundance, and functional pathways. RESULTS: Independent microbial signatures were detected for PD (P = 4E-5), participants' region of residence within the United States (P = 3E-3), age (P = 0.03), sex (P = 1E-3), and dietary fruits/vegetables (P = 0.01). Among patients, independent signals were detected for catechol-O-methyltransferase-inhibitors (P = 4E-4), anticholinergics (P = 5E-3), and possibly carbidopa/levodopa (P = 0.05). We found significantly altered abundances of the Bifidobacteriaceae, Christensenellaceae, [Tissierellaceae], Lachnospiraceae, Lactobacillaceae, Pasteurellaceae, and Verrucomicrobiaceae families. Functional predictions revealed changes in numerous pathways, including the metabolism of plant-derived compounds and xenobiotics degradation. CONCLUSION: PD is accompanied by dysbiosis of gut microbiome. Results coalesce divergent findings of prior studies, reveal altered abundance of several taxa, nominate functional pathways, and demonstrate independent effects of PD medications on the microbiome. The findings provide new leads and testable hypotheses on the pathophysiology and treatment of PD. © 2017 International Parkinson and Movement Disorder Society.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1002/mds.26942
Canonical
link ↗
Fetched
2026-06-12 MST

Cite this

APA
Hill‐Burns, E.M., Debelius, J.W., Morton, J.T., Wissemann, W.T., Lewis, M.R., Wallen, Z.D., Peddada, S.D., Factor, S.A., Molho, E., Zabetian, C.P., Knight, R., &amp; Payami, H. (2017). Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. <em>Movement Disorders</em>. https://doi.org/10.1002/mds.26942
Vancouver
Hill‐Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Movement Disorders. 2017. doi:10.1002/mds.26942.
BibTeX
@article{erin2017Parkin, title = {Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome}, author = {Erin M. Hill‐Burns and Justine W. Debelius and James T. Morton and William T. Wissemann and Matthew R. Lewis and Zachary D. Wallen and Shyamal D. Peddada and Stewart A. Factor and Eric Molho and Cyrus P. Zabetian and Rob Knight and Haydeh Payami}, journal = {Movement Disorders}, year = {2017}, doi = {10.1002/mds.26942}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings